J&J Sues Sun to Block Generic Copies of Cancer Drug Yondelis

J&J’s Janssen and partner Pharma Mar filed a patent-infringement suit to block generic-drug companies from selling low-cost versions of the cancer treatment Yondelis.

• A paring of EVenus and Jiangsu Hengrui, as well as a pairing of Natco and Sun, are seeking to sell generic versions of the drug, Janssen and Pharma Mar said a complaint filed Thursday in federal court in Trenton, New Jersey
• Yondelis is chemotherapy for treating patients with specific soft tissue sarcomas
• The copycat drugs would infringe patents owned by Pharma Mar and licensed to Janssen that expire in 2026 and 2028, according to the ...